识别系统性血管炎共享的新风险位点,指向药物重定位的潜在靶基因
研究对8467例系统性血管炎患者和29795例健康对照的全基因组数据行荟萃分析,发现16个变异与两种及以上血管炎独立相关,其中15个为新共享风险位点;CTLA4和CPLX1附近两个信号为新遗传风险位点,药物重定位分析提示阿巴西普和乌司奴单抗等可能被重定位用于所分析血管炎的管理。
要点
- 16个变异与两种及以上血管炎独立相关,15个为新共享风险位点。
- CTLA4和CPLX1附近两个多效性信号为血管炎新遗传风险位点。
- 药物重定位分析提示阿巴西普和乌司奴单抗等可能被重定位用于所分析血管炎的管理。
核心结论
- 研究识别出在血管炎中具有功能影响的新共享风险位点,并 pinpoint 潜在因果基因,其中一些可能代表有前景的血管炎治疗靶点。
研究设计与样本
- 对8467例患有任一主要类型血管炎的患者和29795例健康对照的全基因组数据,使用ASSET进行荟萃分析。
主要发现
- 16个变异与两种或以上血管炎独立相关,其中15个代表新的共享风险位点。
- 位于CTLA4和CPLX1附近的两个多效性信号作为血管炎的新遗传风险位点出现。
- 这些多态性大多似乎通过调节基因表达影响血管炎,基于功能注释优先筛选出的潜在因果基因包括CTLA4、RNF145、IL12B、IL5、IRF1、IFNGR1、PTK2B、TRIM35、EGR2和ETS2。
- 药物重定位分析显示,包括阿巴西普和乌司奴单抗在内的几种药物可能被重定位用于所分析血管炎的管理。
关键数值与推荐
- 16个变异与两种或以上血管炎独立相关,15个为新共享风险位点。
- CTLA4和CPLX1附近两个信号为血管炎新遗传风险位点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The number of susceptibility loci currently associated with vasculitis is lower than in other immune-mediated diseases due in part to small cohort sizes, a consequence of the low prevalence of vasculitides. This study aimed to identify new genetic risk loci for the main systemic vasculitides through a comprehensive analysis of their genetic overlap. METHODS: Genome-wide data from 8467 patients with any of the main forms of vasculitis and 29 795 healthy controls were meta-analysed using ASSET. Pleiotropic variants were functionally annotated and linked to their target genes. Prioritised genes were queried in DrugBank to identify potentially repositionable drugs for the treatment of vasculitis. RESULTS: Sixteen variants were independently associated with two or more vasculitides, 15 of them representing new shared risk loci. Two of these pleiotropic signals, located close to CTLA4 and CPLX1, emerged as novel genetic risk loci in vasculitis. Most of these polymorphisms appeared to affect vasculitis by regulating gene expression. In this regard, for some of these common signals, potential causal genes were prioritised based on functional annotation, including CTLA4, RNF145, IL12B, IL5, IRF1, IFNGR1, PTK2B, TRIM35, EGR2 and ETS2, each of which has key roles in inflammation. In addition, drug repositioning analysis showed that several drugs, including abatacept and ustekinumab, could be potentially repurposed in the management of the analysed vasculitides. CONCLUSIONS: We identified new shared risk loci with functional impact in vasculitis and pinpointed potential causal genes, some of which could represent promising targets for the treatment of vasculitis.
引用
- Ortiz-Fernández L, Carmona EG, Kerick M, et al. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing. Ann Rheum Dis. 2023. PMID: 36797040. doi:10.1136/ard-2022-223697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。